Paper Details

  1. Home
  2. Paper Details

Demyelinating polyradiculoneuropathy during dabrafenib and trametinib treatment for metastatic melanoma: A case report.

Author: BaldessariCinzia, DepenniRoberta, DominiciMassimo, GrecoStefano, PuglieseGiuseppe, VenturelliMarta

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article focuses on the neurological toxicities associated with BRAF and MEK inhibitors, used to treat melanoma patients with BRAF V600E mutation. While these therapies are generally well-tolerated, polyradiculopathy, a rare neurological toxicity, has been reported in recent years.
Paper Details　
Original Abstract of the Article :
Melanoma is an aggressive malignancy, historically characterized with a poor prognosis and few treatment options. The advent of target therapy with BRAF and MEK inhibitors, as well as immunotherapy, changed this scenario and improved the prognosis of patients with BRAF V600E mutation. These therapie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/03008916231202102

データ提供：米国国立医学図書館（NLM）

A Rare Side Effect: Demyelinating Polyradiculoneuropathy During Dabrafenib and Trametinib Treatment

Melanoma, a formidable adversary, has been met with groundbreaking treatments like BRAF and MEK inhibitors. These therapies have dramatically improved the prognosis for many patients, but like a mirage in the desert, they can sometimes reveal unexpected side effects. This study describes a rare case of demyelinating polyradiculoneuropathy, a neurological complication, occurring during treatment with dabrafenib and trametinib, two potent targeted therapies. The authors carefully analyze this unusual case, highlighting the importance of vigilant monitoring for potential neurological side effects.

Navigating the Unexpected: Side Effects of Targeted Therapies

The study emphasizes the importance of being aware of the potential side effects of targeted therapies. While these therapies have revolutionized cancer treatment, they can sometimes lead to unexpected consequences. This case report underscores the need for close monitoring of patients receiving these treatments, allowing for prompt identification and management of any potential complications.

Staying Vigilant: Early Detection and Management

The authors highlight the importance of early detection and management of neurological side effects. Prompt diagnosis and intervention can play a crucial role in minimizing the impact of these complications. The study emphasizes the importance of close collaboration between oncologists and neurologists in ensuring optimal patient care.

Dr.Camel's Conclusion

While targeted therapies have brought hope to many cancer patients, this study reminds us that vigilance is crucial in managing potential side effects. This case report serves as a valuable reminder that even with the most advanced treatments, careful monitoring and prompt intervention are essential in achieving the best possible outcomes.

Date :
  1. Date Completed 2023-12-06
  2. Date Revised 2023-12-06
Further Info :

Pubmed ID

38050794

DOI: Digital Object Identifier

10.1177/03008916231202102

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.